Exenatide improves glycemic control in Type 2 Diabetes at one year « GPCR News

Tags
5-HT1A 5-HT2 5-HT2A 5-HT3 5-HT4 5-ht6 5HT1A 5HT1D 5HT2 5HT2A 5HT3 5HT4 5ht6 agonist Angiotensin II AT1 antagonist Astrazeneca Beta 2 adrenoceptor Cannabinoid CB1 Daiichi-Sankyo Dopamine Dopamine D2 Fentanyl ghrelin GlaxoSmithkline GLP-1 gpcr GSK Histamine H1 Licensing Lilly Merck Muscarinic Opioid Opioid mu phase I phase II phase III Preclinical regulatory Research Sanofi-Aventis TRPV1 Vanilloid
June 2008

M T W T F S S

« May Jul »

1

2 3 4 5 6 7 8

9 10 11 12 13 14 15

16 17 18 19 20 21 22

23 24 25 26 27 28 29

30

Exenatide improves glycemic control in Type 2 Diabetes at one year

Posted on June 11, 2008 by crimsoncanary

Data presented at ADA show that Amylin Pharmaceutical’s GLP-1 analog Exenatide continues to improve glucose control at one year in type 2 diabetes patients.

Filed under: gpcr | Tagged: AC-2993, AC2993, Alkermes, Amylin, Byetta, Exenatide, Exendin-4, Lilly, LY-2148568, LY2148568

« Novel series of sst2-Selective Somatostatin Antagonists Activation of the cannabinoid receptor may have use in Systemic Sclerosis »

Leave a Reply